Equities Analysts Issue Forecasts for Harpoon Therapeutics, Inc.’s FY2024 Earnings (NASDAQ:HARP)

Harpoon Therapeutics, Inc. (NASDAQ:HARP) – Stock analysts at Cantor Fitzgerald decreased their FY2024 EPS estimates for shares of Harpoon Therapeutics in a note issued to investors on Wednesday, September 6th. Cantor Fitzgerald analyst J. Kim now expects that the company will earn ($14.15) per share for the year, down from their prior forecast of ($14.10). The consensus estimate for Harpoon Therapeutics’ current full-year earnings is ($9.00) per share.

A number of other analysts have also recently commented on the stock. 500.com reiterated a “reiterates” rating on shares of Harpoon Therapeutics in a research note on Monday, May 15th. HC Wainwright reiterated a “buy” rating and set a $45.00 price target on shares of Harpoon Therapeutics in a report on Thursday, August 10th. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to MarketBeat.com, Harpoon Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $40.00.

Harpoon Therapeutics Trading Down 2.4 %

NASDAQ:HARP opened at $7.80 on Friday. The stock has a market capitalization of $30.26 million, a PE ratio of -0.66 and a beta of 1.48. Harpoon Therapeutics has a 1-year low of $5.44 and a 1-year high of $33.55. The firm has a fifty day simple moving average of $8.20 and a 200 day simple moving average of $7.43.

Harpoon Therapeutics (NASDAQ:HARP) last posted its quarterly earnings results on Wednesday, August 9th. The company reported $0.30 earnings per share for the quarter, beating analysts’ consensus estimates of ($4.30) by $4.60. Harpoon Therapeutics had a negative return on equity of 620.00% and a negative net margin of 86.73%. The firm had revenue of $20.22 million during the quarter, compared to the consensus estimate of $9.19 million.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of HARP. Renaissance Technologies LLC grew its position in shares of Harpoon Therapeutics by 8.7% in the second quarter. Renaissance Technologies LLC now owns 213,600 shares of the company’s stock valued at $152,000 after purchasing an additional 17,180 shares during the last quarter. Susquehanna International Group LLP grew its holdings in Harpoon Therapeutics by 168.1% in the 1st quarter. Susquehanna International Group LLP now owns 53,949 shares of the company’s stock valued at $40,000 after buying an additional 33,830 shares in the last quarter. Two Sigma Investments LP bought a new position in Harpoon Therapeutics during the 1st quarter worth $42,000. Prudential Financial Inc. acquired a new stake in shares of Harpoon Therapeutics during the first quarter worth $32,000. Finally, Bailard Inc. bought a new stake in shares of Harpoon Therapeutics in the first quarter valued at about $47,000. 74.01% of the stock is owned by institutional investors.

About Harpoon Therapeutics

Harpoon Therapeutics, Inc, a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candidate, including HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors; and HPN217 that is in Phase I clinical trials for the treatment of multiple myeloma.